D&K Healthcare Resources Places Order With Empyrean Bioscience; Regional Pharmaceutical Distributor to Carry Preventx Germ Protection Products.Health/Medical & Business Editors CLEVELAND--(BW HealthWire)--July 10, 2001 Empyrean Bioscience, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). : EMDG EMDG Export Market Development Grants (Australia) EMDG Expeditionary Medical Dental Group (US Air Force overseas medical unit, Iraq) ) has expanded distribution of its infectious disease Infectious disease A pathological condition spread among biological species. Infectious diseases, although varied in their effects, are always associated with viruses, bacteria, fungi, protozoa, multicellular parasites and aberrant proteins known as prions. prevention products with a purchase order and shipment to D&K Healthcare Resources, Inc. D&K Healthcare Resources, Inc. is one of the top 10 pharmaceutical distributors nationally and a leader among regional players, supplying pharmaceuticals, over-the-counter products, health and beauty aids, and related items to over 1,300 pharmacies in more than 24 states throughout the Midwest and South. D&K will carry Empyrean's Preventx(R) branded germ protection program, including the alcohol-free hand sanitizer sanitizer a sanitizing product capable of cleaning and disinfecting; usually a formulation containing a disinfectant and a detergent. and first-aid antiseptic gel and antibacterial towelettes. "D&K has an excellent reputation for selecting quality products for distribution to its expansive, multi-faceted network. With Preventx(R) as the newest addition to D&K's product offerings, we feel we have established a win-win relationship: Empyrean's selling network is significantly expanded and D&K customers will now have the opportunity to buy our revolutionary, alcohol-free, aloe-enriched hand sanitizers and first-aid antiseptics," said Pat Buccilli, Empyrean director of sales. Empyrean is a consumer products company specializing in the marketing, sale and distribution of innovative personal care products designed to prevent the spread of infectious diseases. The company markets a line of germ protection products, derived from the core GEDA GEDA Guam Economic Development Authority gEDA GPL'd Electronic Design Automation (software) GEDA Gujarat Energy Development Authority (India) GEDA Gpl Electronic Design Automation Plus(R) formulation, under the Preventx(R) and Coleman(R) brand names. For more information, see www.empyreanbio.com. Empyrean has a licensing agreement with International Bioscience Corporation, a leading developer of revolutionary medical products, granting Empyrean exclusive U.S. marketing and distribution rights to the GEDA Plus(R) microbicidal contraceptive gel and all derivative products. In vitro in vitro /in vi·tro/ (in ve´tro) [L.] within a glass; observable in a test tube; in an artificial environment. in vi·tro adj. In an artificial environment outside a living organism. studies have shown GEDA Plus(R) to be effective against HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. and other sexually transmitted diseases Sexually transmitted diseases Infections that are acquired and transmitted by sexual contact. Although virtually any infection may be transmitted during intimate contact, the term sexually transmitted disease is restricted to conditions that are largely . The worldwide market for a vaginal microbicide has been estimated to be more than $2 billion. For more information on International Bioscience Corporation, visit www.intlbio.net. This press release includes statements that may constitute forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. The statement regarding "Empyrean's selling network is significantly expanded" is forward-looking in nature. These statements are subject to risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Such risks include, among other factors, the acceptability of the product in the marketplace, and the ability to obtain sufficient capital to fund operations. Additional factors, which could cause actual results to differ materially from expectations in the forward-looking statements, are set forth in the Company's Form 10K-SB annual report filed with the Securities and Exchange Commission. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion